| Time Commitment: | 3 hours and 30 minutes over 56 days |
| Target Professions: | DO, MD, MBBS, Nurse Practitioner, Nurse, Physician Assistant, Social Worker, Physical Therapist, Pharmacist, Healthcare Navigator |
| Target Specialties: | Neurology, Pulmonary/Respiratory Physician, Physiatry/Rehabilitation, Genetics/Genomics, Orthopedic Medicine/Sports Medicine, Pharmacy, Nutrition, Pediatrics |
| Credits Available: | 3.50 AMA PRA Category 1 Credit™ |
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments may help patients live longer, creating unique clinical needs. Adults now make up more than a quarter of patients with SMA. However, there are no specific guidelines for the assessment and treatment of adult patients, leading to gaps in their diagnosis and management. Adult care is complex and requires multidisciplinary care. This collaborative CME provides the opportunity to learn and share best practices that will improve outcomes for patients with SMA.
The following questions are designed to assess your knowledge and practice of patients with SMA.
This module will discuss what to consider when assessing adult patients with SMA.
This module will discuss clinical trial data and updates on disease-modifying SMA therapies for older adolescents and adults.
This module will discuss what to consider in the multidisciplinary management of adult patients with SMA.
The following questions are designed to assess your gained knowledge and practice of patients with SMA.
Key Insights on SMA - During this discussion, we will review the self-study modules.
Putting Evidence into Practice - During this discussion, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and discuss what we will take from this CME into our practice.
Meet Cassandra, a 21-year-old woman with SMA who presents to the clinic to discuss new FDA-approved treatments.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with Spinal Muscular Atrophy (SMA).
